Correlation of Plasma Interleukin-18 Concentration and Severity of Renal Involvement and Disease Activity in Systemic Lupus Erythematosus

Overview

Journal J Nephropathol

Specialty Nephrology

Date 2016 Apr 6

PMID 27047807

Citations 16

Authors

Mohammad Reza Jafari-Nakhjavani

Sima Abedi-Azar

Babak Nejati

Affiliations

Soon will be listed here.

Abstract

Background: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by activation of T and polyclonal B lymphocytes. IL-18 was originally identified as a factor which enhances IFN-γ production and is a potent inducer of the inflammatory mediators by T cells, causing severe inflammatory disorders in SLE.

Objectives: This study aimed to evaluate the association of plasma interlukine-18 (IL-18) concentration and severity of lupus nephritis (LN) and disease activity in SLE patients.

Patients And Methods: In this cross-sectional study, 113 patients with SLE and 50 healthy individuals were examined. Serum level of IL-18 was measured. The severity and activity of the disease was determined by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score. The severity of kidney involvement was studied by renal biopsy, serum creatinine and 24 hours urine protein level.

Results: The mean level of serum IL-18 was significantly higher in the patients than controls (577.67 ± 649.95 versus 60.48 ± 19.53 pg/ml; P < 0.001). In SLE patients with active disease level of serum IL-18 was significantly higher than chronic disease (622.77 ± 716.54 versus 182 ± 184.37 pg/ml; P < 0.001). The serum level of IL-18 was significantly higher in stage IV (P < 0.001) and V (P < 0.001) of patients with LN, than other stages.

Conclusions: The current study showed that the serum IL-18 is significantly higher in the patients than controls and it significantly correlated with sever renal involvement and disease activity in SLE patients.

Citing Articles

The effect of circulating cytokines on the risk of systemic lupus erythematosus: Mendelian randomization and observational study.

Xue D, Qian Y, Tu X, He M, Xing F, Ren Y Immunogenetics. 2024; 76(5-6):315-322.

PMID: 39183206 PMC: 11496328. DOI: 10.1007/s00251-024-01351-x.

Tang Y, Wang D, Chen Y, Xu W, Huang A Front Immunol. 2024; 14:1305590.

PMID: 38164134 PMC: 10757975. DOI: 10.3389/fimmu.2023.1305590.

Evaluation of causal associations between interleukin-18 levels and immune-mediated inflammatory diseases: a Mendelian randomization study.

Wu J, Zhang X, Wu D, Jin O, Gu J BMC Med Genomics. 2023; 16(1):306.

PMID: 38031150 PMC: 10685486. DOI: 10.1186/s12920-023-01744-z.

Serum interleukin-18 and its relationship with subclinical atherosclerosis in systemic lupus erythematosus.

Rezaieyazdi Z, AkbariRad M, Saadati N, Salari M, Orang R, Sedighi S ARYA Atheroscler. 2022; 17(6):1-6.

PMID: 35685451 PMC: 9145840. DOI: 10.22122/arya.v17i0.2126.

Novel Effects of Combination Therapy Through Inhibition of Caspase-1/Gasdermin D Induced-Pyroptosis in Lupus Nephritis.

Cao H, Liang J, Liu J, He Y, Ke Y, Sun Y Front Immunol. 2021; 12:720877.

PMID: 34867948 PMC: 8639704. DOI: 10.3389/fimmu.2021.720877.

References

Gracie J, Forsey R, Chan W, Gilmour A, Leung B, Greer M . A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest. 1999; 104(10):1393-401. PMC: 409841. DOI: 10.1172/JCI7317. View

Gladman D, Goldsmith C, Urowitz M, Bacon P, Bombardier C, Isenberg D . Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol. 1992; 19(4):608-11. View

Holcombe R, Baethge B, Wolf R, Betzing K, Stewart R, HALL V . Correlation of serum interleukin-8 and cell surface lysosome-associated membrane protein expression with clinical disease activity in systemic lupus erythematosus. Lupus. 1994; 3(2):97-102. DOI: 10.1177/096120339400300207. View

Liu T, Jones B . Impaired production of IL-12 in system lupus erythematosus. II: IL-12 production in vitro is correlated negatively with serum IL-10, positively with serum IFN-gamma and negatively with disease activity in SLE. Cytokine. 1998; 10(2):148-53. DOI: 10.1006/cyto.1997.0269. View

Chu M, Wong C, Cai Z, Dong J, Jiao D, Kam N . Elevated Expression and Pro-Inflammatory Activity of IL-36 in Patients with Systemic Lupus Erythematosus. Molecules. 2015; 20(10):19588-604. PMC: 6332178. DOI: 10.3390/molecules201019588. View

Gracie J, Robertson S, McInnes I . Interleukin-18. J Leukoc Biol. 2003; 73(2):213-24. DOI: 10.1189/jlb.0602313. View

Dinarello C . IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol. 1999; 103(1 Pt 1):11-24. DOI: 10.1016/s0091-6749(99)70518-x. View

Yamano T, Higashi T, Nouso K, Nakatsukasa H, Kariyama K, Yumoto E . Serum interferon-gamma-inducing factor/IL-18 levels in primary biliary cirrhosis. Clin Exp Immunol. 2000; 122(2):227-31. PMC: 1905768. DOI: 10.1046/j.1365-2249.2000.01356.x. View

Monteleone G, Trapasso F, Parrello T, Biancone L, Stella A, Iuliano R . Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol. 1999; 163(1):143-7. View

10.

Maczynska I, Millo B, Ratajczak-Stefanska V, Maleszka R, Szych Z, Kurpisz M . Proinflammatory cytokine (IL-1beta, IL-6, IL-12, IL-18 and TNF-alpha) levels in sera of patients with subacute cutaneous lupus erythematosus (SCLE). Immunol Lett. 2005; 102(1):79-82. DOI: 10.1016/j.imlet.2005.08.001. View

11.

Ines L, Silva C, Galindo M, Lopez-Longo F, Terroso G, Romao V . Classification of Systemic Lupus Erythematosus: Systemic Lupus International Collaborating Clinics Versus American College of Rheumatology Criteria. A Comparative Study of 2,055 Patients From a Real-Life, International Systemic Lupus Erythematosus.... Arthritis Care Res (Hoboken). 2015; 67(8):1180-5. DOI: 10.1002/acr.22539. View

12.

Calvani N, Richards H, Tucci M, Pannarale G, Silvestris F . Up-regulation of IL-18 and predominance of a Th1 immune response is a hallmark of lupus nephritis. Clin Exp Immunol. 2004; 138(1):171-8. PMC: 1809179. DOI: 10.1111/j.1365-2249.2004.02588.x. View

13.

Faust J, Menke J, Kriegsmann J, Kelley V, Mayet W, Galle P . Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Faslpr mice with autoimmune lupus nephritis. Arthritis Rheum. 2002; 46(11):3083-95. DOI: 10.1002/art.10563. View

14.

Tucci M, Quatraro C, Lombardi L, Pellegrino C, Dammacco F, Silvestris F . Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum. 2008; 58(1):251-62. DOI: 10.1002/art.23186. View

15.

Griffiths B, Mosca M, Gordon C . Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol. 2005; 19(5):685-708. DOI: 10.1016/j.berh.2005.03.010. View

16.

Dao T, Ohashi K, Kayano T, Kurimoto M, Okamura H . Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell Immunol. 1996; 173(2):230-5. DOI: 10.1006/cimm.1996.0272. View

17.

Mosaad Y, Metwally S, Auf F, Abdel-Samee E, El-Deek B, Limon N . Proinflammatory cytokines (IL-12 and IL-18) in immune rheumatic diseases: relation with disease activity and autoantibodies production. Egypt J Immunol. 2005; 10(2):19-26. View

18.

Biet F, Locht C, Kremer L . Immunoregulatory functions of interleukin 18 and its role in defense against bacterial pathogens. J Mol Med (Berl). 2002; 80(3):147-62. DOI: 10.1007/s00109-001-0307-1. View

19.

Spronk P, ter Borg E, Limburg P, Kallenberg C . Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity?. Clin Exp Immunol. 1992; 90(1):106-10. PMC: 1554549. DOI: 10.1111/j.1365-2249.1992.tb05840.x. View

20.

Robak E, Robak T, Wozniacka A, Zak-Prelich M, Sysa-Jedrzejowska A, Stepien H . Proinflammatory interferon-gamma--inducing monokines (interleukin-12, interleukin-18, interleukin-15)--serum profile in patients with systemic lupus erythematosus. Eur Cytokine Netw. 2002; 13(3):364-8. View